We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+26%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.24B
AUM Growth
+$829M
Cap. Flow
-$224M
Cap. Flow %
-3.09%
Top 10 Hldgs %
63.72%
Holding
51
New
5
Increased
21
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$330M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$190M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$130M
4
ARGX icon
argenx
ARGX
+$109M
5
GPCR icon
Structure Therapeutics
GPCR
+$76.4M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$810M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$373M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$100M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$44.6M
5
NUVL
Nuvalent
NUVL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
51
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-7,000,000
Closed -$810M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Avoro Capital Advisors held 51 positions worth $7.24B, up 13% from $6.41B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Avoro Capital Advisors withdrew a net $224M in Q4 2023, closing 9 positions and reducing 4 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $810M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in State Street SPDR S&P Biotech ETF worth $397M.

  • Avoro Capital Advisors's largest Q4 2023 buy was State Street SPDR S&P Biotech ETF: 4,444,444 shares worth $397M.
  • Avoro Capital Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023, an estimated $190M increase.
  • Avoro Capital Advisors's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $100M.
  • Avoro Capital Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $810M.
  • Avoro Capital Advisors's ten largest holdings make up 64% of its $7.24B portfolio in Q4 2023.
  • Avoro Capital Advisors opened 5 new positions and closed 9 in Q4 2023.
  • Avoro Capital Advisors's portfolio value rose 13% quarter-over-quarter to $7.24B.

Based on Avoro Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.